Table 2.
Baseline demographic and clinical characteristics of the study participants in the across lipid-derived phenogroups
| Variables | Phenogroup 1 (n = 415) | Phenogroup 2 (n = 496) | Phenogroup 3 (n = 444) | P value |
|---|---|---|---|---|
| Age, years | 63.3 (12.5) | 67.1 (11.6) | 59.5 (12.5) | < 0.001 |
| Male, sex | 349 (84.1%) | 350 (70.6%) | 377 (84.9%) | < 0.001 |
| Previous event | ||||
| Myocardial infarction | 19 (4.6%) | 19 (3.8%) | 18 (4.1%) | 0.84 |
| PCI | 13 (3.1%) | 17 (3.4%) | 9 (2.0%) | 0.42 |
| Diabetes | 91 (21.9%) | 90 (18.1%) | 108 (24.3%) | 0.061 |
| Hypertension | 219 (52.8%) | 262 (52.8%) | 219 (49.3%) | 0.49 |
| Dyslipidemia | 46 (11.1%) | 30 (6.0%) | 64 (14.4%) | < 0.001 |
| Chronic kidney disease | 19 (4.6%) | 11 (2.2%) | 10 (2.3%) | 0.084 |
| Smoking status | 301 (72.5%) | 293 (59.1%) | 327 (73.6%) | < 0.001 |
| Time to balloon, h | 6.0 (4.0–11.0) | 6.0 (3.5–11.0) | 5.0 (3.0–9.0) | 0.062 |
| SBP, mmHg | 123.3 (25.5) | 124.9 (26.3) | 127.0 (23.7) | 0.092 |
| HR, bpm | 81.9 (19.2) | 81.0 (19.3) | 83.2 (16.8) | 0.18 |
| BMI, Kg/m2 | 24.0 (3.5) | 23.0 (3.7) | 25.1 (3.4) | < 0.001 |
| Culprit artery | 0.02 | |||
| LAD | 183 (44.1%) | 278 (56.0%) | 227 (51.1%) | |
| LCX | 44 (10.6%) | 62 (8.1%) | 47 (10.6%) | |
| RCA | 178 (42.9%) | 169 (34.1%) | 157 (35.4%) | |
| LM | 4 (1.0%) | 1 (0.2%) | 3 (0.7%) | |
| Multivessel | 6 (1.4%) | 8 (1.6%) | 10 (2.2%) | |
| Gensini score | 56.3 (23.7) | 53.3 (25.2) | 55.2 (26.1) | 0.20 |
| Killip class (> II) | 116 (28.0%) | 142 (28.6%) | 100 (22.5%) | 0.092 |
| Postprocedural TIMI (< II) | 29 (7.0%) | 33 (6.7%) | 25 (5.6%) | 0.71 |
| Hb, g/L | 134.6 (19.2) | 141.5 (20.7) | 137.9 (20.2) | < 0.001 |
| HbA1c, % | 6.6 (1.7) | 6.4 (1.6) | 6.9 (1.7) | < 0.001 |
| Creatinine, μmol/L | 96.6 (33.8) | 81.8 (42.7) | 81.0 (38.8) | < 0.001 |
| FT3, pg/ml | 2.87 (0.51) | 2.87 (0.94) | 2.98 (0.68) | 0.004 |
| FT4, ng/dl | 0.92 (0.21) | 0.95 (0.39) | 0.89 (0.16) | 0.002 |
| hsTSH, μIU/ml | 0.92 (0.57–1.7) | 0.98 (0.54–1.68) | 0.98 (0.53–1.57) | 0.99 |
| cTNI, ug/L | 98.4 (9.8–473.3) | 74.7 (6.9–462.8) | 90.1 (9.1–471.0) | 0.35 |
| NT-proBNP | 0.96 (0.34–186) | 1.33 (0.34–169) | 0.70 (0.27–162) | 0.16 |
| LVEF, % | 55.5 (7.1) | 54.3 (8.1) | 55.3 (7.4) | 0.059 |
| Aspirin | 406 (97.8%) | 489 (98.6%) | 444 (100.0%) | 0.003 |
| Statin | 415 (100.0%) | 494 (99.6%) | 442 (99.5%) | 0.56 |
| Beta-blocker | 336 (81.0%) | 403 (81.3%) | 386 (86.9%) | 0.024 |
| Diuretics | 180 (43.4%) | 219 (44.2%) | 153 (34.5%) | 0.004 |
Abbreviations: CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, SBP systolic blood pressure, HR heart rate, BMI body mass index, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, LM left main artery, TIMI thrombolysis in myocardial infarction, Hb hemoglobin, HbA1c hemoglobin A1c, FT3 free triiodothyronine, FT4 free thyroxine, hsTSH high-sensitive thyroid-stimulating hormone, cTNI cardiac troponin I, NT-proBNP N-terminal pro b-type natriuretic peptide, LVEF left ventricular ejection fraction